[Form 4] Beyond Air, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Beyond Air (XAIR) filed a Form 4 disclosing an option repricing for its CEO and Chairman, Steven A. Lisi. The Board approved an adjustment effective November 4, 2025, reducing the exercise price of multiple existing stock option grants to $1.95 per share, which the filing states was the closing price on November 3, 2025. All other terms of the options remain unchanged.

The Form 4 lists several grant lots that were modified, including blocks such as 47,500 and 40,000 options that previously carried higher exercise prices like $10.80 and $5.892 per share. The options were issued under the company’s Amended and Restated 2013 Equity Incentive Plan and continue to vest per their original schedules, contingent on continued service.

Insights

Executive compensation & governance analyst

Administrative repricing to $1.95; terms and vesting unchanged.

The board-approved adjustment on November 4, 2025 reduces exercise prices on multiple outstanding options to $1.95, matching the stated prior-day close. The filing lists several grants that were moved from higher strikes (e.g., $10.80, $5.892) to the new level.

Per the disclosure, all other terms remain the same and vesting continues under the 2013 Equity Incentive Plan and prior award agreements, dependent on continued service. This is a compensation administration event; cash-flow effects depend on future exercises and are not indicated in the excerpt.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lisi Steven A.

(Last) (First) (Middle)

C/O BEYOND AIR, INC.

900 STEWART AVENUE, SUITE 301

(Street)

GARDEN CITY NY 11530

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Beyond Air, Inc. [ XAIR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and Chairman of the Board

3. Date of Earliest Transaction (Month/Day/Year)
11/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to buy)	$10.8	11/04/2025		D(1)			47,500	(2)	(2)	Common Stock	47,500	(1)	0	D
Stock Options (Right to buy)	$1.95	11/04/2025		A(1)		47,500		(2)	(2)	Common Stock	47,500	(1)	47,500	D
Stock Options (Right to buy)	$10.8	11/04/2025		D(1)			40,000	(2)	(2)	Common Stock	40,000	(1)	0	D
Stock Options (Right to buy)	$1.95	11/04/2025		A(1)		40,000		(2)	(2)	Common Stock	40,000	(1)	40,000	D
Stock Options (Right to buy)	$10.8	11/04/2025		D(1)			14,000	(2)	(2)	Common Stock	14,000	(1)	0	D
Stock Options (Right to buy)	$1.95	11/04/2025		A(1)		14,000		(2)	(2)	Common Stock	14,000	(1)	14,000	D
Stock Options (Right to buy)	$10.8	11/04/2025		D(1)			10,000	(2)	(2)	Common Stock	10,000	(1)	0	D
Stock Options (Right to buy)	$1.95	11/04/2025		A(1)		10,000		(2)	(2)	Common Stock	10,000	(1)	10,000	D
Stock Options (Right to buy)	$10.8	11/04/2025		D(1)			3,500	(2)	(2)	Common Stock	3,500	(1)	0	D
Stock Options (Right to buy)	$1.95	11/04/2025		A(1)		3,500		(2)	(2)	Common Stock	3,500	(1)	3,500	D
Stock Options (Right to buy)	$10.8	11/04/2025		D(1)			12,500	(2)	(2)	Common Stock	12,500	(1)	0	D
Stock Options (Right to buy)	$1.95	11/04/2025		A(1)		12,500		(2)	(2)	Common Stock	12,500	(1)	12,500	D
Stock Options (Right to buy)	$10.8	11/04/2025		D(1)			20,000	(2)	(2)	Common Stock	20,000	(1)	0	D
Stock Options (Right to buy)	$1.95	11/04/2025		A(1)		20,000		(2)	(2)	Common Stock	20,000	(1)	20,000	D
Stock Options (Right to buy)	$5.892	11/04/2025		D(1)			47,500	(2)	(2)	Common Stock	47,500	(1)	0	D
Stock Options (Right to buy)	$1.95	11/04/2025		A(1)		47,500		(2)	(2)	Common Stock	47,500	(1)	47,500	D

Explanation of Responses:

1. On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged.

2. This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

	/s/ Steven A. Lisi	11/06/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Beyond Air (XAIR) disclose in this Form 4?

A board-approved option repricing for CEO Steven A. Lisi, effective November 4, 2025, reducing exercise prices to $1.95 per share.

What is the new exercise price for the repriced options at XAIR?

The exercise price was reduced to $1.95 per share, the stated closing price on November 3, 2025.

Which prior exercise prices were adjusted in the XAIR filing?

Examples include options previously struck at $10.80 and $5.892 per share, now repriced to $1.95.

Do vesting terms change for the repriced Beyond Air options?

No. The filing states all other terms remain unchanged; vesting continues per the award agreements under the 2013 Plan.

Whose options were affected by the repricing at XAIR?

Options held by Steven A. Lisi, CEO and Chairman of the Board, as reported in the Form 4.

Under which plan were the affected options granted at Beyond Air?

The options were issued under the Amended and Restated 2013 Equity Incentive Plan.